Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy (Q24657470)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy	scientific article

Statements

scholarly article

0 references

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy (English)

0 references

mineralocorticoid

0 references

diabetic nephropathy

1 reference

based on heuristic

inferred from title

4

object named as

Gloria L Vega

0 references

Beverley Adams-Huet

2

object named as

Beverley Adams-Huet

0 references

author name string

Uzma F Mehdi

1

0 references

Philip Raskin

3

0 references

Robert D Toto

5

0 references

language of work or name

0 references

publication date

December 2009

0 references

Journal of the American Society of Nephrology

0 references

20

0 references

2641-50

0 references

12

0 references

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

7 April 2017

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

7 April 2017

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

7 April 2017

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

7 April 2017

Aldosterone and glomerular podocyte injury

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 September 2017

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 September 2017

The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 September 2017

Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 September 2017

Aldosterone antagonism in chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 September 2017

Proteinuria reduction: mandatory consideration or option when selecting an antihypertensive agent?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 September 2017

Aldosterone in the development and progression of renal injury

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 September 2017

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 September 2017

Aldosterone receptor blockade and the role of eplerenone: evolving perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 September 2017

The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 September 2017

Prognosis in diabetic nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 September 2017

Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

30 May 2018

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 November 2018

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 November 2018

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 November 2018

Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 November 2018

Diabetic nephropathy: Linking histology, cell biology, and genetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 November 2018

The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 November 2018

Effect of aldosterone on renal transforming growth factor-beta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 November 2018

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 November 2018

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 November 2018

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 November 2018

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2794224

28 November 2018

A method for estimating nitrogen intake of patients with chronic renal failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of Arterial Blood Pressure and Albuminuria on the Progression of Diabetic Nephropathy in IDDM Patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19926893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1681%2FASN.2009070737

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1681/ASN.2009070737

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

release_ls5c5dtdmfd5zpd2i5rut7ezyq

1 reference

https://api.fatcat.wiki/v0/release/ls5c5dtdmfd5zpd2i5rut7ezyq

24 November 2022

based on heuristic

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24657470&oldid=2086467742"